Uso de sacubitril/valsartán en pacientes hospitalizados en vida real

  1. López García, Juan Carlos
Supervised by:
  1. F. Fernández Avilés Director
  2. Manuel Martínez-Sellés Director

Defence university: Universidad Complutense de Madrid

Fecha de defensa: 02 February 2021

Committee:
  1. Juan Tamargo Menéndez Chair
  2. Juan Francisco Delgado Jiménez Secretary
  3. José Luis Zamorano Gómez Committee member
  4. Esteban López de Sá Committee member
  5. Pedro Luis Sánchez Fernández Committee member

Type: Thesis

Teseo: 155153 DIALNET lock_openDocta Complutense editor

Abstract

Sacubitril/valsartan is safe when initiated during hospitalization in a clinical trial setting. Its safety in real-life population is not stablished. We compared the initiation of sacubitril/valsartan during hospitalization in a non-selected population, in Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in the Patients Stabilized From an Acute Heart Failure Episode (PIONEER-HF) trial, and in non-selected outpatients. Methods. Multicentre registry including 527 patients: 100 were started on sacubitril/valsartan during hospitalization (19.0%) and 427 as outpatients (81.0%). Clinical, analytical, and echocardiographic variables, previous therapies, and the starting dose of sacubitril/valsartan and its modification or suspension were collected throughout the follow-up...